Proceeds expected to extend cash runway into H2 2027 VANCOUVER, British Columbia, Dec. 26, 2023 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Capital, LLC (“EcoR1 Capital”), for the sale of an [...]
VANCOUVER, British Columbia, Dec. 15, 2023 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will become effective prior to the market open on Monday, December 18, [...]
VANCOUVER, British Columbia, Nov. 30, 2023 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 42nd Annual J.P. Morgan Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings on January 8-11, 2024 and a corporate presentation on January 11th, [...]